Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950193 | 0.86 | GRM2 (0.61) | GRM2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL29950085 | 0.86 | GRM2 (0.61) | GRM2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL28849018 | 0.86 | GRM2 (0.61) | GRM2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL9823169 | 0.86 | GRM2 (0.61) | GRM2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL9823246 | 0.84 | ALDH1A1 (0.53) | GRM2CYP2C9CYP1A2CYP2C19SIGMAR1 | |
| SCHEMBL4761279 | 0.81 | GRM2 (0.46) | GRM2CYP2C9CYP1A2CYP2C19SIGMAR1 | |
| SCHEMBL4277020 | 0.81 | GRM2 (0.57) | GRM2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL16701320 | 0.79 | CALML3 (0.49) | GRM2CYP2C9CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL16701317 | 0.79 | CALML3 (0.49) | GRM2CYP2C9CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL4094183 | 0.78 | F10 (0.59) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637667-B2 | Method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives | LEGOCHEM BIOSCIENCE LTD. (KR) | 2014-01-28 | — | — | US | disclosed |
| US-20120108808-A1 | METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108808-A1 | METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES | F2, F11, F5 | GRM2 4466/4885CYP2C9 62/4885CYP1A2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.